MR contrast injector debuts

Article

Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris

Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris is compatible with MR scanners ranging from 0.2T to 2T. The company introduced its first-generation Solaris in 1996.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.